The Extraordinary General Meeting of ChronTech Pharma AB

The Extraordinary General Meeting of ChronTech Pharma AB was held in Stockholm on November 25, 2011.

The meeting resolved to amend the Articles of Association with regards to the limits of the maximum and minimum share capital and maximum and minimal outstanding shares. The resolution means that the share capital shall amount to a minimum of 5.1 million SEK and a maximum of 20.4 million SEK and also that the number of outstanding shares shall amount to a minimum of 170 million and a maximum of 680 million.

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Mobile phone: +46 709 28 05 28,
E-mail: anders.vahlne@ki.se

About ChronTech

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.